Should LDL-C Be Intensified Earlier in Hypertensive Filipino Adults? Evidence for Treating Shared Cardiovascular Risk, Not Isolated Numbers

In a hypertensive adult without ASCVD, when should I start a high-intensity statin?

Use a high-intensity statin in primary prevention only when overall ASCVD risk is high enough to justify 50% LDL-C lowering — not for hypertension alone. In a hypertensive adult without ASCVD, the clearest triggers are LDL-C ≥190 mg/dL, diabetes with sufficiently high risk, or very high estimated primary-prevention ris

Which risk enhancers make LDL-C of 70–189 mg/dL more concerning in hypertension?

In a hypertensive adult with LDL-C 70–189 mg/dL, LDL becomes more concerning when there are additional risk enhancers that increase the likelihood of atherosclerotic cardiovascular disease (ASCVD) and may push you toward earlier or more intensive statin therapy. In the Philippine dyslipidemia guideline, these are used

Should LDL-C intensification proceed before blood pressure is fully controlled in a high-risk patient?

Yes — in a high-risk patient, LDL-C intensification should generally proceed even if blood pressure is not yet fully controlled, provided there is no immediate hypertensive emergency or other instability. Hypertension and dyslipidemia are additive/synergistic ASCVD risk factors, and Philippine guidance treats both as p

How should statin intolerance be confirmed and managed before moving to ezetimibe or bempedoic acid?

Before labelling a patient as statin intolerant, confirm that symptoms are truly statin-related, exclude secondary causes, and document inability to tolerate at least 2 statin regimens (typically including one at the lowest approved dose), because most patients can still take some statin exposure with dose reduction, s

LDL-C, non-HDL-C, apoB, or Lp(a)? Which marker best refines risk in hypertensive patients with CKD or metabolic syndrome?

Assuming adult hypertensive patients being risk-stratified in routine practice: For hypertensive patients with CKD or metabolic syndrome, LDL-C remains the primary treatment target, but non-HDL-C or apoB usually best refines residual atherogenic risk when triglycerides are elevated, obesity/insulin resistance is presen